Id: acc4984
Group: 1sens
Protein: DR5
Gene Symbol: TNFRSF10B
Protein Id: O14763
Protein Name: TR10B_HUMAN
PTM: ubiquitination
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype:
Disease Cellline: A549
Disease Info:
Drug: IITZ-01
Drug Info: "IITZ - 01 is a drug. However, due to limited information, a more detailed academic description cannot be provided. "
Effect: enhance
Effect Info: "IITZ-01 downregulates the E3 ubiquitin ligase Cbl, inhibits the ubiquitination and degradation of DR5, and enhances its membrane expression, thereby enhancing TRAIL-induced apoptosis."
Note:
Score: 5.0
Pubmed(PMID): 32825566
Sentence Index:
Sentence:

Sequence & Structure:

MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVLPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGVNMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIEDHLLSSGKFMYLEGNADSAMS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed hepatocellular carcinoma ClinicalTrials
TNFRSF10B DROZITUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Terminated chondrosarcoma ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed pancreatic carcinoma ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed non-small cell lung carcinoma ClinicalTrials
TNFRSF10B DROZITUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed non-small cell lung carcinoma ClinicalTrials
TNFRSF10B DULANERMIN Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed non-small cell lung carcinoma ClinicalTrials
TNFRSF10B DROZITUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed non-Hodgkins lymphoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed metastatic colorectal cancer ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Terminated metastatic colorectal cancer ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed liver cancer ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 2 Completed ovarian cancer ClinicalTrials
TNFRSF10B LEXATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Terminated Ewing sarcoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed Hodgkins lymphoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed diffuse large B-cell lymphoma ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed lymphoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed lymphoma ClinicalTrials
TNFRSF10B LEXATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Terminated neuroblastoma ClinicalTrials
TNFRSF10B LEXATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Terminated osteosarcoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed sarcoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Withdrawn pancreatic carcinoma ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed non-small cell lung carcinoma ClinicalTrials
TNFRSF10B LEXATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Terminated rhabdomyosarcoma ClinicalTrials
TNFRSF10B TIGATUZUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed colorectal neoplasm ClinicalTrials
TNFRSF10B CONATUMUMAB Tumor necrosis factor receptor superfamily member 10B agonist 1 Completed non-Hodgkins lymphoma ClinicalTrials
TNFRSF10B DULANERMIN Tumor necrosis factor receptor superfamily member 10B agonist 1 Terminated non-Hodgkins lymphoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: